CDK 5 is a major regulator of the tumor suppressor DLC 1

The Rockefeller University Press $30.00 J. Cell Biol. Vol. 207 No. 5 627–642 www.jcb.org/cgi/doi/10.1083/jcb.201405105 JCB 627 *B.K. Tripathi and X. Qian contributed equally to this paper. Correspondence to Douglas R. Lowy: lowyd@mail.nih.gov; or Brajendra K. Tripathi: tripathib@mail.nih.gov Abbreviations used in this paper: HBEC, human bronchial epithelial cell; IB, immunoblotting; IP, immunoprecipitation; MEF, mouse embryonic fibroblast; NCI, National Cancer Institute; NSCLC, non-small cell lung cancer; pMRLC, phosphorylated myosin regulatory light chain; Rho-GAP, Rho–GTPase activating protein; ROCK, Rho-kinase; WCE, whole cell extract; WT, wild type. Introduction

[1]  F. Ko,et al.  Regulation of deleted in liver cancer 1 tumor suppressor by protein–protein interactions and phosphorylation , 2014, International journal of cancer.

[2]  J. Bibb,et al.  The role of Cdk5 in neuroendocrine thyroid cancer. , 2013, Cancer cell.

[3]  C. Der,et al.  CRL4A-FBXW5–mediated degradation of DLC1 Rho GTPase-activating protein tumor suppressor promotes non-small cell lung cancer cell growth , 2013, Proceedings of the National Academy of Sciences.

[4]  J. Bibb,et al.  Cyclin dependent kinase 5 is required for the normal development of oligodendrocytes and myelin formation. , 2013, Developmental biology.

[5]  D. Lowy,et al.  Inactivation of the Dlc1 gene cooperates with downregulation of p15INK4b and p16Ink4a, leading to neoplastic transformation and poor prognosis in human cancer. , 2012, Cancer research.

[6]  A. Arif.  Extraneuronal activities and regulatory mechanisms of the atypical cyclin-dependent kinase Cdk5. , 2012, Biochemical pharmacology.

[7]  J. Massagué.  TGFβ signalling in context , 2012, Nature Reviews Molecular Cell Biology.

[8]  J. Rosales,et al.  Level of cdk5 expression predicts the survival of relapsed multiple myeloma patients , 2012, Cell cycle.

[9]  D. O’Day,et al.  The cyclin‐dependent kinase inhibitor roscovitine inhibits kinase activity, cell proliferation, multicellular development, and Cdk5 nuclear translocation in Dictyostelium discoideum , 2012, Journal of cellular biochemistry.

[10]  B. Zhao,et al.  Differential regulation of the activity of deleted in liver cancer 1 (DLC1) by tensins controls cell migration and transformation , 2012, Proceedings of the National Academy of Sciences.

[11]  L. Tsai,et al.  Cyclin-dependent kinases in brain development and disease. , 2011, Annual review of cell and developmental biology.

[12]  D. Lowy,et al.  Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK) , 2011, Proceedings of the National Academy of Sciences.

[13]  E. Wilczek,et al.  Deleted in liver cancer protein family in human malignancies (Review). , 2011, Oncology letters.

[14]  Gang Wu,et al.  Expression of CDK5/p35 in resected patients with non-small cell lung cancer: relation to prognosis , 2011, Medical oncology.

[15]  S. Alahari,et al.  Role of Rho GTPases and their regulators in cancer progression. , 2011, Frontiers in bioscience.

[16]  M. Mann,et al.  Andromeda: a peptide search engine integrated into the MaxQuant environment. , 2011, Journal of proteome research.

[17]  J. Cherfils,et al.  Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? , 2010, Nature Reviews Cancer.

[18]  M. V. Vijayakumar,et al.  Cdk5 phosphorylates non-genotoxically overexpressed p53 following inhibition of PP2A to induce cell cycle arrest/apoptosis and inhibits tumor progression , 2010, Molecular Cancer.

[19]  G. Feldmann,et al.  Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling. , 2010, Cancer research.

[20]  G. Hicks,et al.  Identification and characterization of Dlc1 isoforms in the mouse and study of the biological function of a single gene trapped isoform , 2010, BMC Biology.

[21]  S. Lo,et al.  DLC2 modulates angiogenic responses in vascular endothelial cells by regulating cell attachment and migration , 2010, Oncogene.

[22]  P. Zelenka,et al.  Cdk5-Dependent Regulation of Rho Activity, Cytoskeletal Contraction, and Epithelial Cell Migration via Suppression of Src and p190RhoGAP , 2009, Molecular and Cellular Biology.

[23]  D. Lowy,et al.  The Tensin-3 protein, including its SH2 domain, is phosphorylated by Src and contributes to tumorigenesis and metastasis. , 2009, Cancer cell.

[24]  P. Khong,et al.  Deleted in Liver Cancer 2 (DLC2) Was Dispensable for Development and Its Deficiency Did Not Aggravate Hepatocarcinogenesis , 2009, PloS one.

[25]  S. Chien,et al.  Role of Focal Adhesion Kinase Ser-732 Phosphorylation in Centrosome Function during Mitosis* , 2009, Journal of Biological Chemistry.

[26]  C. Der,et al.  Role of DLC-1, a tumor suppressor protein with RhoGAP activity, in regulation of the cytoskeleton and cell motility , 2009, Cancer and Metastasis Reviews.

[27]  Boon Chuan Low,et al.  The SAM domain of the RhoGAP DLC1 binds EF1A1 to regulate cell migration , 2009, Journal of Cell Science.

[28]  M. Mann,et al.  MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification , 2008, Nature Biotechnology.

[29]  C. Der,et al.  Effects of Structure of Rho GTPase-activating Protein DLC-1 on Cell Morphology and Migration , 2008, Journal of Biological Chemistry.

[30]  Igor Jurisica,et al.  Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study , 2008, Nature Medicine.

[31]  A. Ridley,et al.  Rho GTPases in cancer cell biology , 2008, FEBS letters.

[32]  K. Hahn,et al.  DLC‐1 suppresses non‐small cell lung cancer growth and invasion by RhoGAP‐dependent and independent mechanisms , 2008, Molecular carcinogenesis.

[33]  M. Stepp,et al.  The Cdk5 inhibitor olomoucine promotes corneal debridement wound closure in vivo , 2008, Molecular vision.

[34]  J. Chan,et al.  Cdk5 regulates differentiation of oligodendrocyte precursor cells through the direct phosphorylation of paxillin , 2007, Journal of Cell Science.

[35]  M. Taoka,et al.  Regulation of the interaction of Disabled‐1 with CIN85 by phosphorylation with Cyclin‐dependent kinase 5 , 2007, Genes to cells : devoted to molecular & cellular mechanisms.

[36]  John G. Collard,et al.  Rho GTPases: functions and association with cancer , 2007, Clinical & Experimental Metastasis.

[37]  I. Amit,et al.  A reciprocal tensin-3–cten switch mediates EGF-driven mammary cell migration , 2007, Nature Cell Biology.

[38]  M. Guan,et al.  Deleted in liver cancer 3 (DLC-3), a novel Rho GTPase-activating protein, is downregulated in cancer and inhibits tumor cell growth , 2007, Oncogene.

[39]  Kenneth M. Yamada,et al.  Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities , 2007, Proceedings of the National Academy of Sciences.

[40]  Shih-Yi Lin,et al.  Cdk5 Regulates STAT3 Activation and Cell Proliferation in Medullary Thyroid Carcinoma Cells* , 2007, Journal of Biological Chemistry.

[41]  S. Lo,et al.  The phosphotyrosine-independent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1 , 2007, The Journal of cell biology.

[42]  M. Mann,et al.  In-gel digestion for mass spectrometric characterization of proteins and proteomes , 2006, Nature Protocols.

[43]  I. Ng,et al.  Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression. , 2006, Cancer research.

[44]  K. Herrup,et al.  Cyclin-Dependent Kinase 5 Is Essential for Neuronal Cell Cycle Arrest and Differentiation , 2005, The Journal of Neuroscience.

[45]  J. Bowie,et al.  The Many Faces of SAM , 2005, Science's STKE.

[46]  S. Thorgeirsson,et al.  DLC‐1, a Rho GTPase‐activating protein with tumor suppressor function, is essential for embryonic development , 2005, FEBS letters.

[47]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[48]  I. Ng,et al.  Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma. , 2003, Cancer research.

[49]  G. Johnson,et al.  Cdk5 phosphorylates p53 and regulates its activity , 2002, Journal of neurochemistry.

[50]  L. Tsai,et al.  Cables Links Cdk5 and c-Abl and Facilitates Cdk5 Tyrosine Phosphorylation, Kinase Upregulation, and Neurite Outgrowth , 2000, Neuron.

[51]  C. Ponting,et al.  START: a lipid-binding domain in StAR, HD-ZIP and signalling proteins. , 1999, Trends in biochemical sciences.

[52]  Veeranna,et al.  Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[53]  C. González-Billault,et al.  Going out of the brain: non-nervous system physiological and pathological functions of Cdk5. , 2012, Cellular signalling.

[54]  Joshua E. Elias,et al.  Target-Decoy Search Strategy for Mass Spectrometry-Based Proteomics , 2010, Proteome Bioinformatics.

[55]  M. Mann,et al.  Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips , 2007, Nature Protocols.

[56]  M. Hoshino,et al.  Cdk5 phosphorylates and stabilizes p27kip1 contributing to actin organization and cortical neuronal migration , 2006, Nature Cell Biology.